Profile data is unavailable for this security.
About the company
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
- Revenue in USD (TTM)92.39m
- Net income in USD-52.70m
- Incorporated2021
- Employees285.00
- LocationPrenetics Global LtdUnit 701-706, K11 Atelier King's Road,728 King's Road, Quarry Bay Hong KongHKG
- Phone+852 22109588
- Websitehttps://ir.prenetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 200.50m | 61.00 | -- | 2.15 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 204.15m | 55.00 | -- | 3.14 | -- | 53.70 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Quantum-Si Inc | 3.18m | -116.85m | 204.28m | 143.00 | -- | 0.8686 | -- | 64.30 | -0.6589 | -0.6589 | 0.0176 | 1.09 | 0.0128 | 0.404 | 3.58 | 22,216.78 | -47.06 | -- | -50.90 | -- | 51.65 | -- | -3,677.97 | -11,135.53 | 10.59 | -- | 0.00 | -- | 182.62 | -- | -5.26 | -- | -- | -- |
| Humacyte Inc | 1.57m | -36.97m | 206.51m | 218.00 | -- | -- | -- | 131.45 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 208.31m | 3.00 | -- | -- | -- | 3,472.48 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Prenetics Global Ltd | 92.39m | -52.70m | 215.68m | 285.00 | -- | 0.9907 | -- | 2.33 | -3.60 | -4.02 | 6.58 | 15.43 | 0.443 | 6.38 | 22.48 | -- | -26.36 | -55.58 | -31.23 | -71.68 | 52.97 | 47.68 | -59.49 | -381.63 | 2.76 | -13.87 | 0.01 | -- | 479.76 | 7.23 | -51.06 | -- | 77.92 | -- |
| Heron Therapeutics Inc | 154.90m | -20.20m | 216.82m | 128.00 | -- | 16.30 | -- | 1.40 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 218.62m | 32.00 | -- | 56.53 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 218.67m | 12.00 | -- | 2.99 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 221.31m | 23.00 | -- | 2.71 | -- | 33.48 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 224.74m | 174.00 | -- | 0.9593 | -- | 2.30 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 226.29m | 172.00 | -- | 1.03 | -- | 7.23 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Surrozen Inc | 3.60m | -86.91m | 230.14m | 40.00 | -- | -- | -- | 63.86 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 230.50m | 25.00 | -- | 6.80 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 230.74m | 13.00 | -- | 12.15 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 230.92m | 15.00 | -- | 1.96 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Prenetics Global Ltd's reporting currency: US Dollar USD
8.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Eastspring Investments (Singapore) Ltd.as of 31 Dec 2025 | 427.96k | 3.42% |
| Nomura Global Financial Products, Inc.as of 31 Dec 2025 | 268.00k | 2.14% |
| Jane Street Capital LLCas of 31 Dec 2025 | 82.68k | 0.66% |
| 683 Capital Management LLCas of 31 Dec 2025 | 75.00k | 0.60% |
| Millennium Management LLCas of 31 Dec 2025 | 51.43k | 0.41% |
| Marshall Wace LLPas of 31 Dec 2025 | 50.03k | 0.40% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 42.25k | 0.34% |
| Qube Research & Technologies Ltd.as of 31 Dec 2025 | 31.14k | 0.25% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 30.13k | 0.24% |
| Fifth Lane Capital LPas of 31 Dec 2025 | 30.00k | 0.24% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
